754-10-9 | Pivalamide

Packsize	Purity	Availability	Price	Discounted Price
5g	97%	in stock	$11.00	$8.00
10g	97%	in stock	$13.00	$9.00
25g	97%	in stock	$13.00	$9.00
100g	97%	in stock	$40.00	$28.00
500g	97%	in stock	$186.00	$130.00

Description

• Catalog Number: AB46890
• Chemical Name: Pivalamide
• CAS Number: 754-10-9
• Molecular Formula: C5H11NO
• Molecular Weight: 101.1469
• MDL Number: MFCD00008011
• SMILES: NC(=O)C(C)(C)C
• NSC Number: 17584

Computed Properties

• Complexity: 80.6
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 7
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 0.5

Literature

• Characterization of cobalt(III) hydroxamic acid complexes based on a tris(2-pyridylmethyl)amine scaffold: reactivity toward cysteine methyl ester.

  Inorganic chemistry 20120903

• Synthesis and characterization of cobalt(II) complexes with tripodal polypyridine ligand bearing pivalamide groups. Selective formation of six- and seven-coordinate cobalt(II) complexes.

  Dalton transactions (Cambridge, England : 2003) 20120414

• Array of Love-wave sensors based on quartz/Novolac to detect CWA simulants.

  Talanta 20110915

• Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide.

  The Prostate 20110701

• N-(2-Chloro-phenyl-sulfon-yl)-2,2-dimethyl-propanamide.

  Acta crystallographica. Section E, Structure reports online 20110601

• Syntheses, characterization, and photochemical properties of amidate-bridged Pt(bpy) dimers tethered to Ru(bpy)3(2+) derivatives.

  Dalton transactions (Cambridge, England : 2003) 20110421

• Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.

  PLoS computational biology 20110401

• 2,2-Dimethyl-N-(2-methyl-phenyl-sulfon-yl)propanamide.

  Acta crystallographica. Section E, Structure reports online 20110201

• On the curvature in logarithmic plots of rate coefficients for chemical reactions.

  Chemistry Central journal 20110101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• N-(Phenyl-sulfon-yl)acetamide.

  Acta crystallographica. Section E, Structure reports online 20100601

• Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.

  Journal of medicinal chemistry 20091126

• (Cryptand-222)potassium(+) (hydrogensulfido)[5,10,15,20-tetra-kis(2-pival-amido-phen-yl)porphyrinato]ferrate(II).

  Acta crystallographica. Section E, Structure reports online 20090801

• N-tert-Butyl-3-hydr-oxy-5-androstene-17-carboxamide monohydrate.

  Acta crystallographica. Section E, Structure reports online 20090701

• Addition of mild electrophiles to a Mo[triple bond]N triple bond and nitrile synthesis via metal-mediated N-atom transfer to acid chlorides.

  Journal of the American Chemical Society 20081203

• Fe(II) mononuclear complexes with a new aminopyridyl ligand bearing a pivaloylamido arm. Preparation and spectroscopic characterizations of a Fe(III)-hydroperoxo complex with oxygen and nitrogen donors.

  Inorganic chemistry 20070305

• The strength of hydrogen bonding to metal-bound ligands can contribute to changes in the redox behaviour of metal centres.

  Dalton transactions (Cambridge, England : 2003) 20060521

• Human serum albumin hybrid incorporating tailed porphyrinatoiron(II) in the alpha,alpha,alpha,beta-conformer as an O2-binding site.

  Bioconjugate chemistry 20060101

• Preparation, structure characterization, and oxidation activity of ruthenium complexes with tripodal ligands bearing noncovalent interaction sites.

  Inorganic chemistry 20041213

• Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.

  Bioorganic & medicinal chemistry letters 20020902

• Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen.

  Anti-cancer drug design 20010201